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Predictors of response to entecavir therapy 113Results: The rates of serum alanine aminotransferase (ALT) normalization at treatment Year
1 and Year 2 were 86% and 88%, respectively. The cumulative rate of HBeAg loss at treatment
Year 1 and Year 2 were 17% and 33.3%, respectively. The rates of undetectable levels of serum
hepatitis B virus (HBV) deoxyribonucleic acid (DNA) at treatment Year 1 and Year 2 were 64%
and 80.8%, respectively. In univariate analysis, HBeAg loss at 2 years was associated with a
young age (35 years; pZ 0.007) and a high baseline ALT level (p < 0.001). Multivariate anal-
ysis after adjusting for age, sex, and ALT level [>5 times the upper limit of normal (ULN)]
showed that a young age (odds ratio, 2.66; 95% confidence interval, 1.2e5.92) and male sex
(odds ratio, 0.36; 95% confidence interval, 0.16e0.83) were independent factors associated
with HBeAg loss at 2 years of therapy.
Conclusion: Two-year entecavir therapy has good biochemical and virologic responses; howev-
er, the rate of HBeAg loss is modest in HBeAg-positive CHB patients. A young age (i.e., 35
years) and female sex were also associated with a better serologic response.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC.Open access under CC BY-NC-ND license.Introduction
Hepatitis B virus (HBV) infection affects 350 million people
and leads to >600,000 premature deaths annually
throughout the world [1,2]. It can be complicated by acute
hepatitis, hepatic failure, cirrhosis, or hepatocellular car-
cinoma (HCC). After the development of the hepatitis B
vaccine, the incidence of acute HBV infection has remark-
ably decreased. However, chronic hepatitis B (CHB) infec-
tion still produces a considerable health burden worldwide.
Therapy with interferon (IFN) or nucleos(t)ide analogues
(NAs) reduces hepatic inflammation and liver-related com-
plications in CHB patients [3,4]. However, these treatment
modalities still have limitations. First, the chance of hep-
atitis B surface antigen (HBsAg) seroclearancedwhich can
clinically represent a cure of HBV infectiondis rare [5,6].
Second, hepatitis B e antigen (HBeAg) seroconversion in
HBeAg-positive CHB patients is usually considered a satis-
factory endpoint of treatment in several treatment guide-
lines. The efficacy of IFN or NAs remains modest in terms of
serologic response [7,8]. Third, the new generations of NAs
such as entecavir and tenofovir, which have a high antiviral
potency and genetic barrier to drug resistance, can achieve
profound viral suppression, although prolonged or even
infinite treatment may increase the economic burden. To
improve the cost-effectiveness of anti-HBV treatment,
favorable baseline and on-treatment predictors of response
should be identified to select patients who can benefit the
most from treatment.
Two clinical trials and real-world data confirm the high
efficacy and low drug resistance profile of entecavir
treatment, although factors associated with favorable re-
sponses remain unclear [9,10]. Our recent study showed
that the baseline viral load and serum alanine amino-
transferase (ALT) level were correlated with the serologic
response in CHB patients treated with 3-year entecavir
therapy [11]. However, the primary endpoint was the cu-
mulative HBeAg loss and the duration of treatment ranged
1e6 years. To further identify favorable predictors of
HBeAg loss in HBeAg-positive CHB patients treated with
short-term entecavir therapy, we studied 132 treatment-
naı¨ve patients treated with 2-year entecavir therapy.Methods
Patients
This study population was selected from the “treatment-
CHB” cohort, as previously described [11]. In brief, 132
compensated treatment-naı¨ve HBeAg-positive CHB patients
who had received entecavir (0.5 mg) therapy for >2 years
were recruited from six hospitals between May 2005 and
July 2010. All patients had a history of HBsAg for >6
months, but did not have hepatitis C and D virus coinfection
or any other known causes of hepatitis. Liver decompen-
sation was defined as a total bilirubin level >2 mg/dL or a
prolonged prothrombin time (i.e., >3 seconds, compared to
normal controls). Cirrhosis was diagnosed based on histo-
logical findings or on ultrasonographic evidence of a
nodular liver surface with a coarse echotexture [12].
Treatment response was defined according to the following
criteria: (1) a biochemical response with normalization of
serum ALT level, (2) a serologic response with HBeAg loss
and/or seroconversion with the presence of anti-HBe anti-
body, and (3) a virologic response with an undetectable
level of serum HBV deoxyribonucleic acid (DNA), based on
real-time polymerase chain reaction (PCR) assay. The pri-
mary endpoint was HBeAg loss after 2 years of entecavir
treatment.
The serum levels of ALT, HBV DNA, HBeAg, and anti-HBe
antibody status were measured at baseline, at 3 months of
treatment, at 6 months of treatment, and every 6 months
thereafter. For HCC surveillance, a liver ultrasound exam-
ination was performed and the serum alpha-fetoprotein
level was measured every 6 months. Virologic breakthrough
was defined as follows: (1) an increase in the HBV DNA level
to >1 log10 IU/mL from the nadir for patients with
detectable HBV DNA levels, or (2) an increase in the HBV
DNA level to more than the lower limit of the detectable
level for patients who had achieved undetectable HBV DNA
levels during entecavir treatment. Virologic breakthrough
was confirmed on two occasions at least 1 month apart. The
add-on treatment using adefovir can be reimbursed for 3
years by the guidelines of the Bureau of National Health
Insurance in New Taipei City, Taiwan.
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Biochemical data such as the levels of aspartate amino-
transferase (AST) and ALT were measured using an auto-
analyzer (Roche Analytics; Roche Professional Diagnostics,
Penzberg, Germany). The cutoff value of the serum ALT
level was 40 U/L. The levels of HBeAg and anti-HBe
antibody were measured using the Abbott Architect
i2000 immunology analyzer (Abbott Diagnostics, IL, USA).
Among the six hospitals, the HBV DNA levels were
measured by four methods: (1) the Cobas Taqman HBV
assay (Roche Molecular Systems Inc., Branchburg, NJ,
USA); (2) an inhouse PCR; (3) the Abbott RealTime HBV
assay (Abbott Molecular Inc., Des Plaines, IL, USA); and (4)
the Cobas Amplicor HBV monitor test (Roche Molecular
Systems, Inc.) with a detection limit range from <6 IU/mL
up to 200 IU/mL. In the hospital where the Cobas Amplicor
HBV monitor test was used, the HBV DNA levels were
measured again after dilution if the data were beyond the
upper limit of the linear range. There were four patients
with baseline HBV DNA levels beyond the upper limit of
detectable range: three patients had a HBV DNA level
>1.1  108 IU/mL and one patient had a HBV DNA level
>6.4  108 IU/mL. The upper limit of HBV DNA levels were
used for statistical analysis.
Ethical considerations
The study was performed in accordance with the principles
of the 1975 Declaration of Helsinki, and was approved by
the Institutional Review Board of each participating center.
Each patient provided written informed consent.
Statistical analysis
Continuous variables such as age, serum ALT level, and
HBV DNA levels were expressed by their median values
and range. Categorical variables were tested using the
frequency table and the Chi-square test. Continuous var-
iable testing included table and the paired t test. The
factors associated with HBeAg loss were analyzed using
logistic regression analysis. Statistical analyses were per-
formed using SAS 9.1 software (SAS Institute Inc., Cary,
NC, USA). A value of p < 0.05 was considered statistically
significant.Table 1 Demographic data and baseline characteristics.a
Variable Total, N Z
Sex (male), n (%) 93 (71)
Cirrhosis, n (%) 20 (15)
Age (y), median (range) 40.2 (17.8
Baseline HBV DNA (log10 IU/mL), N, median (range) 110, 7.3 (
Baseline ALT, median (range) 324.4 (27
Genotype B, n/N (%) 40/59 (68
Undetectable HBV DNA at week 24, n/N (%) 35/102 (3
ALT Z alanine aminotransferase; HBeAg Z hepatitis B e antigen; HB
a Categorical variables are assessed by Fisher’s exact test. ContinuoResults
Baseline patient demographics and clinical
characteristics
Table 1 summarizes the patients’ demographics and baseline
characteristics. The median age at enrollment was 40.2
years (range, 17.8e70.2 years). There were 93 (71%) males
and 39 (29%) females. Of these patients, 20 (15%) patients
had cirrhosis, which was confirmed by liver biopsy in 6 (30%)
patients and by ultrasound in the remaining 14 (70%) pa-
tients. However, the data of the baseline HBVDNA level were
available for 110 (83.3%) patients; the median level was 7.3
log10 IU/mL (range, 3e13 log10 IU/mL). Based on the reim-
bursement guidelines of Taiwan, if HBeAg-positive patients
have a serum ALT level more than five times the upper limit
of normal (ULN), an antiviral agent can be administered
without the data of HBV DNA level. In addition, a small
number of patients with self-paid drugs also lacked baseline
HBVDNA levels. Themedian baseline ALT levelwas 324.4 U/L
(range, 30e2415 U/L). Two patients who received entecavir
treatment with a baseline ALT level of<40 U/L had cirrhosis.
Virologic breakthrough was noted in two (1.5%) patients who
had good compliance. Genotype data were available for 59
patientsd40 patients were genotype B and 19 patients were
genotype C. At Week 24, HBV DNA levels were available for
102 patients; of these, undetectable levels of HBV DNA was
confirmed in 35 (34%) patients.
Response to treatment
The rates of ALT normalization at Year 1 and Year 2 were
86% and 88%, respectively. The rates of HBeAg loss at Year 1
and Year 2 were 17% and 33.3%, respectively. The rate of
HBeAg seroconversion at Year 2 was 22% (29 of 132 pa-
tients). The rates of undetectable HBV DNA levels at Year 1
and Year 2 were 64% (73 of 114 patients; data missing for 18
patients) and 80.8% (97 of 120 patients; data missing for 12
patients), respectively.
Comparison between patients with and without
HBeAg loss at Year 2
The patients with HBeAg loss at Year 2, compared to pa-
tients without HBeAg loss, were younger (34.2 years vs.132 HBeAg loss at
2 years, N Z 44
No HBeAg loss at
2 years, N Z 88
p
26 (59) 67 (76) 0.068
4 (9) 16 (18) 0.205
e70.2) 34.2 (20.6e59.7) 42.3 (17.8e70.2) 0.007
3e13) 33, 7.6 (4e9) 77, 7.8 (3e13) 0.109
e2415) 274.5 (40e1622) 131.0 (27e2415) <0.001
) 13/16 (81) 27/43 (63) 0.177
4) 12/35 (34) 23/67 (34) 0.997
V Z hepatitis B virus.
us variables are assessed by the ManneWhitney U test.
Table 2 Factors associated with hepatitis B e antigen loss with 2-year entecavir treatment.
Factors HBeAg loss after
2 years, N Z 44;
n (%)
No HBeAg loss
after 2 years,
N Z 88; n (%)
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Age  35 y 23 (52) 61 (69) 2.47 (1.16e5.21) 0.022 2.66 (1.20e5.92) 0.017
Male sex 26 (59) 67 (76) 0.46 (0.21e0.99) 0.068 0.36 (0.16e0.83) 0.017
Baseline ALT 5  ULN 13 (30) 44 (50) 0.42 (0.19e0.91) 0.027 0.48 (0.21e1.03) 0.060
ALTZ alanine aminotransferase; CIZ confidence interval; HBeAgZ hepatitis B e antigen; ORZ odds ratio; ULNZ upper limit of normal.
Predictors of response to entecavir therapy 11542.3 years, respectively; p Z 0.007) and had higher serum
ALT levels (274.5 U/L vs. 131 U/L, respectively; p < 0.001).
The frequency of male sex tended to be lower in patients
with HBeAg loss (p Z 0.068; Table 1).
Factors associated with HBeAg loss at Year 2, based
on univariate and multivariate analyses
In univariate analysis, a young age (35 years; p Z 0.007)
and a high baseline ALT level (p < 0.001) were associated
with a greater serologic response at Year 2. Female sex had
a trend association (p Z 0.068; Table 1). Undetectable
levels of HBV DNA at Week 24 were not associated with
HBeAg loss. After adjusting for age, sex, and ALT level (i.e.,
>5 times the ULN), multivariate analysis showed that a
young age (odds ratio, 2.66; 95% confidence interval,
1.2e5.92), and male sex (odds ratio, 0.36; 95% confidence
interval, 0.16e0.83) were independent factors associated
with HBeAg loss at Year 2 (Table 2). Fig. 1 shows the rates of
HBeAg loss after 2 years of entecavir treatment, based on
age and sex. Table 3 shows the rates of HBeAg loss in CHB
patients grouped by age and sex. The odds ratio (95% con-
fidence interval) between the best and worst groups was
10.42 (2.37e45.9).
Discussion
In this real-world study, 132 compensated treatment-naı¨ve
HBeAg-positive CHB patients were treated with entecavir.Figure 1 The HBeAg loss rate at 2 years of entecavir treat-
ment, based on age and sex. HBeAg Z hepatitis B e antigen.Our data indicated that entecavir could achieve good
biochemical and virologic responses but it has a modest
serologic response after 2 years of treatment. Furthermore,
female sex and a young age (<35 years) were positively
associated with the rate of HBeAg loss. For example, the
HBeAg loss rate at 2 years of entecavir treatment was 46%
in young patients, and increased up to 72.7% in young fe-
male patients.
Hepatitis B e antigen loss and/or seroconversion usually
confer a decline in viral replication and subsequent clinical
remission [13]. Therefore, a serologic response is a satis-
factory endpoint during treatment by NAs or interferon for
HBeAg-positive CHB patients. Our results showed that age
and sex were associated with HBeAg loss with <2 years of
entecavir treatment, which suggests that the effectiveness
of short-term entecavir treatment was better in patients
<35 years or in female patients. Thus, entecavir may be
considered a first-line agent in this special clinical setting if
current guidelines of initiating antiviral treatment are met.
Current guidelines recommend initiating NAs treatment
for CHB patients once they enter the immune clearance
phase [14,15]. The indications include hepatic decompen-
sation, significant fibrosis/cirrhosis, or a high viral load with
ALT elevation (>2 times the ULN). Our recent study
demonstrated that young CHB patients (i.e., <30 years)
with NAs-induced HBeAg seroconversion had a higher risk of
HBV reactivation, compared to patients with spontaneous
HBeAg seroconversion [16]. These young HBeAg-positive
CHB patients were usually in the early stage of the im-
mune clearance phase and may have a chance of sponta-
neous HBeAg seroconversion after hepatitis flares.
Therefore, we suggest that 3e6 months of close observa-
tion may be more appropriate than immediate NAs treat-
ment in young and compensated HBeAg-positive CHB
patients. In the current study, the rate of HBeAg loss was
33% after 2 years of entecavir treatment. A young age of
<35 years was a favorable predictor for HBeAg loss and had
an odds ratio of 2.66, which suggests that the effectiveness
of entecavir treatment may be reduced in patients >35
years. Taking these lines of evidence together, age should
be considered an important factor in starting NAs treat-
ment for HBeAg-positive CHB patients.
Among the various NAs, lamivudine was the first antiviral
drug approved for the treatment of CHB. In an Asian hep-
atitis lamivudine trial [17], the patients with an ALT level
more than five times the ULN had the highest rate of HBeAg
seroconversion, compared to patients with an ALT level
2e5 times the ULN or patients with an ALT level less than
two times the ULN. A Chinese study of patients undergoing
2 years of lamivudine treatment showed that the serum
Table 3 The rate of hepatitis B e antigen loss in entecavir-treated chronic hepatitis B patients grouped by age and sex and the
odds ratio between the best and worst groups.
Grouped by age and sex, n/N (%) Odds ratio (95% confidence interval)
Younger and female Older and female Younger and male Older and male Younger and female vs. Older and male
8/11 (73) 10/28 (36) 15/39 (38) 11/54 (20) 10.42 (2.37, 45.9)
116 W.-C. Su et al.HBV DNA level at Week 24 could predict therapeutic effi-
cacy and virologic breakthrough [17,18]. In patients who
underwent 2 years of telbivudine treatment, baseline levels
of HBV DNA at <9 log10 copies per milliliter and serum ALT
at greater than two times the ULN were favorable pre-
dictors for HBeAg-positive patients. Undetectable HBV DNA
levels at Week 24 were the best on-treatment predictor for
HBeAg-positive and for negative patients [19]. In another
study of HBeAg-positive CHB patients who received 3 years
of telbivudine treatment, patients with a significant decline
of quantitative HBsAg at 6 months of treatment had a
higher rate of HBsAg seroclearance, compared to patients
without this decline [20].
Regarding the predictors of entecavir treatment, our
previous study showed that the viral load and the serum ALT
level were correlated with the serologic response in
entecavir-treated CHB patients. A recent study also showed
that an ALT level of greater than five times the ULN was
associated with HBsAg seroclearance [21]. For the short-
term response to entecavir treatment, our study confirmed
that an age <35 years and female sex were associated with
HBeAg loss after 2 years of entecavir treatment.
Our study had some unique features. International
treatment guidelines suggest that NAs can be stopped while
achieving HBeAg loss and/or seroconversion with adequate
consolidation therapy in HBeAg-positive CHB patients. To
the best of our knowledge, this was the first study to find the
favorable predictors of serologic response after short-term
(i.e., 2-year) entecavir treatment. Therefore, we could
choose “super-responders” prior to starting treatment, and
these patients had a higher probability of achieving thera-
peutic endpoint and avoiding infinite treatment.
However, this study has a few limitations. In this multi-
center retrospective study, four different assays were used
to measure the serum HBV DNA levels, and some patients
lacked baseline HBV DNA levels. The possible bias produced
by different laboratories could be minimized by using the
international unit. The data of the HBV genotype were
available in 59 (44.7%) patients in this real-world study.
Furthermore, the percentage of missing HBV DNA data was
still in the acceptable range (16.7%) and the real-world
data were not selected by any intention. Therefore, the
major conclusions would not be undermined. In addition,
the primary therapeutic endpoint was HBeAg loss instead of
the virologic response. Thus, favorable predictors may not
be influenced by the different detection limits of HBV DNA
assays.
In conclusion, a young age (i.e., 35 years) and female
sex are favorable predictors of HBeAg loss with 2-year
entecavir treatment in treatment-naı¨ve HBeAg-positive
CHB patients. Because older patients may have a reduced
response to entecavir treatment, age rather than viral load,ALT level, fibrosis stage, and status of compensation should
be considered when initiating antiviral therapy.
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